S100A5 and cancer: Importantly, the negative correlation between S100A5, the cancer‐immune cycle, and TIICs was validated in the Xiangya cohort (Figure 1C; Table S2, Supporting Information), indicating a robust predictive value of S100A5 for TIICs in BLCA.